Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONCO | PRESS-RELEASE | bearish | 5/10 | Onconetix announces a 1-for-10 reverse stock split effective May 21, 2026, to regain compliance with Nasdaq's $1 minimum | May 19, 2026 |
| ARTV | PRESS-RELEASE | neutral | 4/10 | Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and Head of R&D. Dr. Miralles brings >20 years of dr | May 19, 2026 |
| PSTV | PRESS-RELEASE | neutral | 4/10 | Plus Therapeutics announced a strategic partnership with Ephemeral Technologies, an AI firm founded by former Palantir h | May 19, 2026 |
| ZBIO | PRESS-RELEASE | bullish | 7/10 | Zenas BioPharma announced that the Phase 3 INDIGO trial of obexelimab in IgG4-Related Disease met its primary endpoint a | May 19, 2026 |
| CGEM | PRESS-RELEASE | bullish | 5/10 | Cullinan Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its CLN-049, a FLT3xCD3 T cell eng | May 19, 2026 |
| XRTX | 6-K, PRESS-RELEASE | bearish | 6/10 | XORTX closed a $5M public offering of 2.66M common shares/pre-funded warrants at $1.88/share, representing massive dilut | May 19, 2026 |
| NAII | PRESS-RELEASE | bearish | 6/10 | NAII reported Q3 FY2026 net sales of $35.5M (+23% YoY) but net loss widened to -$4.3M (-$0.72 EPS) from -$2.2M (-$0.37 E | May 19, 2026 |
| CMND | PRESS-RELEASE | bearish | 5/10 | Clearmind Medicine announces a 1-for-10 reverse stock split effective May 21, 2026, to regain compliance with Nasdaq's m | May 19, 2026 |
| RLAY | PRESS-RELEASE | bullish | 7/10 | Relay Therapeutics reported promising initial Phase 2 data for zovegalisib in PIK3CA-driven vascular anomalies, showing | May 19, 2026 |
| CGEM | PRESS-RELEASE | neutral | 5/10 | Cullinan Therapeutics announced that interim Phase 1 data for CLN-978 (CD19xCD3 T cell engager) in RA and SLE will be pr | May 18, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix announced completion of patient enrollment in the Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblasto | May 18, 2026 |
| WVE | PRESS-RELEASE | bullish | 7/10 | Wave Life Sciences reported strong updated Phase 1b/2a data for WVE-006 in AATD, showing restoration of wild-type M-AAT | May 18, 2026 |
| MLYS | PRESS-RELEASE | neutral | 4/10 | Mineralys Therapeutics announced that new data from its Phase 3 LAUNCH-HTN trial of lorundrostat in patients with uncont | May 18, 2026 |
| UPB | PRESS-RELEASE | bullish | 7/10 | Upstream Bio presented positive Phase 2 VIBRANT trial data at ATS 2026, showing verekitug improved asthma control and na | May 18, 2026 |
| NTHI | PRESS-RELEASE | bearish | 6/10 | NeOnc reported Q1 2026 EPS of -$0.38, a 245.5% miss vs consensus of -$0.11, with zero revenue. The net loss improved YoY | May 18, 2026 |
| DWTX | PRESS-RELEASE | bullish | 7/10 | Dogwood Therapeutics announced the commencement of a 12-week open-label extension study for its lead candidate Halneuron | May 18, 2026 |
| SCNX | PRESS-RELEASE | bullish | 6/10 | Scienture reported Q1 2026 revenue of $56K (up 449% YoY from $10K) and EPS of -$0.08, beating consensus of -$0.23 by 65. | May 18, 2026 |
| FBIO | PRESS-RELEASE | neutral | 2/10 | Fortress Biotech announced CEO participation in a fireside chat at A.G.P.'s Virtual Healthcare Conference. The filing is | May 18, 2026 |
| SLXN | PRESS-RELEASE | bullish | 7/10 | Silexion received Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in locally advanced pancre | May 18, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced the formation of a wholly owned Nevada subsidiary, Quantum Drones Corporation, to pursue U.S. go | May 18, 2026 |
| TEVA | PRESS-RELEASE | neutral | 3/10 | Teva presented new IMPACT-TD Registry data at the 2026 APA Annual Meeting, revealing that 85% of young adults (18-29) wi | May 18, 2026 |
| CRVO | PRESS-RELEASE | mixed | 6/10 | CervoMed reported Q1 2026 EPS of -$0.86, beating consensus of -$0.98 by 12.2%, but net loss widened to -$8.0M from -$4.9 | May 18, 2026 |
| NGEN | PRESS-RELEASE | bearish | 6/10 | NervGen Pharma reported Q1 2026 net loss of $1.7M ($0.09 diluted EPS) vs consensus $-0.07, a 28.6% miss on the Street-qu | May 18, 2026 |
| REGN | PRESS-RELEASE | neutral | 4/10 | Regeneron announced a strategic research collaboration with Parabilis Medicines to discover Antibody-Helicon Conjugates | May 18, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced participation as an exhibitor at SOF Week 2026, a premier defense convention. The event provides | May 18, 2026 |
| NRXP | PRESS-RELEASE | bullish | 6/10 | NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1. | May 18, 2026 |
| DSGN | PRESS-RELEASE | bullish | 8/10 | Design Therapeutics announced positive Phase 1/2 RESTORE-FA data for DT-216P2 in Friedreich ataxia, showing dose-depende | May 18, 2026 |
| CNTX | PRESS-RELEASE, 8-K | bullish | 7/10 | Context Therapeutics amended its license agreement with BioAtla for CT-202, buying out all future milestone and royalty | May 18, 2026 |
| CATX | PRESS-RELEASE | neutral | 3/10 | Perspective Therapeutics announced first patient dosing in two new cohorts of its Phase 1/2a trials for [212Pb]VMT-α-NET | May 18, 2026 |
| DSGN | PRESS-RELEASE | bullish | 8/10 | Design Therapeutics will announce Phase 1/2 RESTORE-FA trial data for DT-216P2 in Friedreich's ataxia on May 18, 2026. T | May 17, 2026 |